| Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017 |
161 |
| Association between insulin resistance and the development of cardiovascular disease |
110 |
| SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart |
53 |
| Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies |
42 |
| Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis |
38 |
| The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation |
36 |
| Class effects of SGLT2 inhibitors on cardiorenal outcomes |
34 |
| Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure |
34 |
| SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial |
33 |
| Diabetes, cardiovascular disease and the microcirculation |
33 |
| Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study |
32 |
| The effect of dapagliflozin treatment on epicardial adipose tissue volume |
32 |
| Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy |
30 |
| Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study |
29 |
| Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes |
28 |
| SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(-/-) mice |
27 |
| Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis |
25 |
| SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice |
25 |
| Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury |
25 |
| Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program) |
24 |
| A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
24 |
| Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review |
23 |
| Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome |
23 |
| How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial |
22 |
| GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data |
22 |
| Association between triglyceride glucose index and arterial stiffness in Korean adults |
22 |
| Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors |
22 |
| Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials |
21 |
| The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats |
21 |
| Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases |
20 |
| New dual peroxisome proliferator activated receptor agonistSaroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence |
20 |
| Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes |
20 |
| Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management |
20 |
| Platelet activity and hypercoagulation in type 2 diabetes |
20 |
| Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice |
19 |
| Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial |
19 |
| Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy |
19 |
| Lower extremity arterial disease in patients with diabetes: a contemporary narrative review |
19 |
| Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study |
18 |
| Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care |
18 |
| ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus |
18 |
| Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword |
18 |
| Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats |
17 |
| MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin |
17 |
| The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study |
17 |
| Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus |
17 |
| Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis |
16 |
| Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study |
15 |
| Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction |
15 |
| HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients |
15 |
